What Brain+ does

Brain+ A/S is a Danish digital therapeutics company founded in 2012 and headquartered in Copenhagen, operating with a headcount of 11–50 employees. The company develops mobile and web applications that deliver evidence-based Cognitive Stimulation Therapy (CST) for people with dementia, positioned as the only non-drug dementia therapy recommended by NICE and endorsed by Cochrane Reviews and SCIE. Its product portfolio centers on three offerings: Ayla, a UK-focused digital CST delivery platform for care homes and NHS memory clinics; CST-Therapist Companion, a Danish municipal channel product being scaled through a seven-municipality consortium with the Danish Alzheimer's Association and DanAge; and CST-Home Care, a product in development to extend therapy into patients' homes with family caregiver support.

The underlying platform combines a structured 14-session CST programme aligned to the official CST Manual, a library of over 180–200 clinically validated activities tagged by cognitive, physical, and emotional requirements, on-screen facilitator guidance that eliminates session preparation, and an outcomes-tracking framework that produces evidence aligned to the UK Single Assessment Framework and CQC reporting requirements. Brain+ monetizes Ayla via an annual SaaS subscription priced at £2,500 per care home per year, with no per-user fees and unlimited onboarding, training, and reporting included. Distribution is direct via the company website with a sales-led motion combining demo booking and quote-request CTAs, targeting care home CEOs, owners, managers, and activity coordinators, alongside NHS memory clinics and primary care providers.

The company's commercial strategy relies heavily on non-dilutive public funding: it secured three Danish public grants in 2023 totaling approximately DKK 7 million (including a DKK 3.5M Danish Business Authority grant for CST-Therapist Companion commercialization and an EUopSTART grant from the Danish Innovation Fund supporting an EIC Accelerator application for CST-Home Care). Geographic footprint is limited to the United Kingdom and Denmark, with no disclosed presence in other markets. The company is privately held and appears to be in an early commercial stage, using public grants in lieu of equity dilution to fund product and geographic expansion.

Name

Brain+

Legal name

Brain+ A/S

Website

https://brain-plus.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Brain+ A/S is a Danish digital therapeutics company developing mobile and web applications that deliver evidence-based Cognitive Stimulation Therapy for dementia patients. It serves UK care homes, NHS memory clinics, Danish municipalities, and home-based dementia care through its Ayla, CST-Therapist Companion, and CST-Home Care products.

Ownership category

akta.pro rank

Product category

Digital Therapeutics / Dementia Care Software

NAICS

Services for the Elderly and Persons with Disabilities (62412), Home Health Care Services (6216)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Home Health Care Services (8082), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Cognitive Stimulation & Reminiscence Therapy (Non-Clinical) (HSABAEAH)

akta.pro secondary industries

Dementia Care Coordination & Care Planning (HSABAEAJ), Dementia/Alzheimer’s Care Management & Behavioral Support (HLADALAF)

Keywords

• Digital dementia therapy
• Cognitive stimulation therapy
• Dementia care software
• Digital therapeutics platform
• Care home technology

Headquarters

HQ city

Copenhagen

HQ country

Denmark

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Annual Care Home Subscription: SaaS subscription model charging a flat annual fee per care home. Includes unlimited platform access, full onboarding and live support, outcomes reporting, and unlimited staff training per site. No per-user fees or hidden charges. Single pricing tier at £2,500/year per care home.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Brain+ develops and sells digital therapeutics software that enables care teams to deliver Cognitive Stimulation Therapy (CST) for dementia patients. Its flagship product Ayla is a SaaS platform providing a structured 14-session CST programme with over 180 evidence-based activities, on-screen facilitator guidance, outcome tracking for CQC and family reporting, and a recognised staff qualification pathway, sold as a £2,500/year subscription per care home. The company also offers CST-Therapist Companion for Danish municipal dementia care and is developing CST-Home Care for home-based therapy delivery.

Product overview

Brain+ offers a portfolio of digital dementia therapy products centered on Cognitive Stimulation Therapy (CST). The primary products include Ayla (a UK-focused CST delivery platform for care homes and memory clinics), CST-Therapist Companion (targeting Danish municipal healthcare), and CST-Home Care (a product in development for home-based therapy). Ayla serves as the flagship consumer-facing product with structured 14-session CST programs, over 200 activities, outcome tracking, and regulatory compliance features, while CST-Therapist Companion and CST-Home Care represent geographic and use-case expansions into institutional and home-based dementia care markets.

Differentiator

Problem solved

Functional benefit

Brands

• CST-Therapist Companion: Digital dementia therapy tool designed to help care teams deliver Cognitive Stimulation Therapy in clinical and care home settings.
• CST-Home Care

Products and services

• Ayla Ayla is the UK's first digital tool designed to help care teams deliver Cognitive Stimulation Therapy (CST) with ease. It provides a 14-session CST programme aligned to the official CST Manual, over 200 evidence-based activities, on-screen guidance with no prep required, one-day training for carers and activity staff, and outcome tracking for CQC and family reporting. It is sold to UK care homes, NHS memory clinics, and primary care providers as a £2,500/year per-care-home subscription.
• CST-Therapist Companion CST-Therapist Companion is a digital dementia therapy product designed to enhance the commercialisation of Cognitive Stimulation Therapy across Danish municipalities, supporting implementation and scaling of therapist-led CST delivery in Danish municipal care services.
• CST-Home Care CST-Home Care is a digital Cognitive Stimulation Therapy product in development that aims to extend Brain+'s dementia therapy delivery into patients' homes, enabling family caregivers and patients living independently to access guided CST sessions outside clinical and care home settings.

Quantifiable outcome

• Delays cognitive decline by 4–6 months — comparable to medication outcomes for dementia
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• Seven Danish MunicipalitiescoreStrategic or Co-development Partner · 23 November 2023Seven Danish municipalities are collaborating with Brain+ on a project (supported by the Danish Business Promotion Board grant nomination) to scale the CST-Therapist Companion software into municipal dementia care. These municipal partners are directly involved in piloting and implementing the digital therapy across their care services.
• Danish Alzheimer's AssociationcoreStrategic or Co-development Partner · 23 November 2023The Danish Alzheimer's Association (Alzheimerforeningen) is collaborating with Brain+ on the project to scale CST-Therapist Companion into Danish dementia care. As the leading patient advocacy organisation for dementia in Denmark, the Association provides clinical legitimacy, patient community access, and strategic guidance for the digital therapy rollout.
• DanAgesupportingStrategic or Co-development Partner · 23 November 2023DanAge (a Danish organisation focused on aging and older adults) is a project collaborator with Brain+ and the seven municipalities on scaling the digital dementia therapy. DanAge contributes expertise on the needs of aging populations and helps ensure the therapy meets the practical requirements of Danish elderly care services.

Scale indicators4 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• NeuronUP: NeuronUP is a digital platform that provides cognitive stimulation and neurorehabilitation activities for professionals working with older adults and patients with cognitive impairment. It directly competes with Brain+ in offering structured, evidence-based cognitive stimulation content to care homes and clinicians, with overlapping activities, personalisation, and outcome tracking features.
• Active Cues (Tovertafel): Active Cues develops the Tovertafel, an interactive projection-based games system for people with dementia and intellectual disabilities, widely deployed in UK and European care homes. It competes for the same care home activity budget as Brain+ Ayla, offering dementia engagement content, though delivered through projected games rather than a structured CST programme.
• Memory Lane Games: Memory Lane Games builds dementia-friendly quiz and reminiscence apps deployed in UK care homes and NHS settings. It is a direct peer to Brain+ Ayla in targeting activity coordinators and dementia leads with digital tools that deliver cognitive engagement and reminiscence content to care home residents.
• Active Minds: Active Minds is a UK-based company designing activities, games, and resources specifically for people with dementia, sold to care homes and dementia services. It competes directly with Brain+ Ayla for the UK care home activity budget, though its offering is predominantly physical products and puzzles rather than a CST software platform.

Broad incumbents

• Posit Science (BrainHQ): Posit Science's BrainHQ is one of the most established clinically validated brain-training platforms, used in research and by older adults for cognitive exercises. It is a broad incumbent in the digital cognitive training category, overlapping with Brain+ in the underlying cognitive stimulation domain though lacking Brain+'s CST-specific clinical alignment and UK care home focus.

Emerging players

• Constant Therapy: Constant Therapy is a digital cognitive, speech, and language therapy platform used by clinicians and patients recovering from stroke, TBI, and dementia. It is an emerging player in digital cognitive rehabilitation that overlaps with Brain+ in dementia cognitive therapy delivery but is broader in clinical indication and more clinician-led.
• MindMate: MindMate is a digital brain health app offering cognitive exercises, lifestyle content, and dementia-friendly activities for users and caregivers. It is an emerging player that intersects with Brain+ in the dementia cognitive engagement category, though primarily consumer-facing rather than focused on UK care home CST delivery.
• Music Health (Vera): Music Health's Vera is a music therapy app for people with dementia, deployed in care homes and used by caregivers. It is an emerging player in the broader non-pharmacological dementia therapy category that overlaps with Brain+'s care home channel and dementia engagement mission, though focused on music rather than CST.
• Cognivive: Cognivive develops digital therapeutics targeting cognitive function in neurological conditions, including dementia. It is an emerging player in the digital dementia therapeutics category with partial overlap to Brain+'s CST-aligned platform, though with a different therapeutic mechanism and earlier-stage commercial footprint.

Others

• Alzheimer's Society: Alzheimer's Society is the UK's leading dementia charity and an advocacy, information, and service-delivery organisation for people with dementia and their families. It is adjacent rather than competitive, serving as a potential partner, content validator, and demand-signaling channel for Brain+ Ayla in the UK dementia ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/2917297
• Xx.com/TheBrainPlus
• Facebookfacebook.com/brain.plus.training

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brain+